Aytu BioScience (AYTU) Stock Forecast & Price Target

Aytu BioPharma is supported by EXXUA’s favorable clinical profile, with effective depressive-symptom relief and labeling that does not include warnings for sexual dysfunction or weight gain versus placebo, which could strengthen differentiation in a competitive antidepressant market. Its commercial launch in Q4 2025, including mid-December 2025 and sales force training completed in mid-January 2026, has been described as highly encouraging and positive, suggesting early traction as the company’s growth focus shifts toward EXXUA. The bullish case is reinforced by conservative estimates for FY27 of $68 million to $70 million in revenue and a swing from a modest net loss to net income by FY28, while the stock trades well below implied future sales and offers significant upside potential.

Aytu BioPharma is exposed to significant fundamental risk despite the large U.S. major depression market, as 21.0 million adults had at least one major depressive episode in 2021, showing the opportunity is attractive but highly competitive and difficult to penetrate. Its outlook is weighed down by balance sheet and liquidity concerns, dependence on successful commercialization, and the risk that product candidates may fail to demonstrate safety and efficacy in clinical trials or after FDA/postmarket approval. The company also faces reimbursement, regulatory, and demand uncertainty, plus broader biotech sentiment and macroeconomic pressure, all of which could limit adoption and erode value.